CytomX Therapeutics Inc’s recent filing unveils that its CEO McCarthy Sean A. unloaded Company’s shares for reported $22556.0 on Mar 18 ’25. In the deal valued at $0.60 per share,37,656 shares were sold. As a result of this transaction, McCarthy Sean A. now holds 995,195 shares worth roughly $0.64 million.
Then, Ogden Christopher sold 8,551 shares, generating $5,122 in total proceeds. Upon selling the shares at $0.60, the Chief Financial Officer now owns 201,026 shares.
Before that, Chu Yu-Waye sold 4,025 shares. CytomX Therapeutics Inc shares valued at $2,411 were divested by the Chief Medical Officer at a price of $0.60 per share. As a result of the transaction, Chu Yu-Waye now holds 135,725 shares, worth roughly $86864.0.
Piper Sandler upgraded its CytomX Therapeutics Inc [CTMX] rating to an Overweight from a a Neutral in a research note published on May 28, 2024; the price target was increased to $3.50 from $2.25. A number of analysts have revised their coverage, including Wedbush’s analysts, who increased its forecast for the stock in early May from “a Neutral” to “an Outperform”. Jefferies also remained covering CTMX and has increased its forecast on May 06, 2024 with a “Buy” recommendation from previously “Hold” rating. JP Morgan revised its rating on April 22, 2024. It rated CTMX as “a Neutral” which previously was an “an Underweight”.
Price Performance Review of CTMX
On Monday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock jump 1.21% to $0.64. Over the last five days, the stock has lost -5.08%. CytomX Therapeutics Inc shares have fallen nearly -38.27% since the year began. Nevertheless, the stocks have fallen -70.97% over the past one year. While a 52-week high of $5.85 was reached on 01/06/25, a 52-week low of $0.56 was recorded on 03/13/25. SMA at 50 days reached $0.7376, while 200 days put it at $1.0623.
Levels Of Support And Resistance For CTMX Stock
The 24-hour chart illustrates a support level at 0.5890, which if violated will result in even more drops to 0.5422. On the upside, there is a resistance level at 0.6666. A further resistance level may holdings at 0.6974. The Relative Strength Index (RSI) on the 14-day chart is 44.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0044, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.05%. Stochastics %K at 47.57% indicates the stock is a holding.
How much short interest is there in CytomX Therapeutics Inc?
A steep rise in short interest was recorded in CytomX Therapeutics Inc stocks on 2025-03-14, growing by 4.6 million shares to a total of 9.0 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.4 million shares. There was a rise of 51.14%, which implies that there is a positive sentiment for the stock.
